Fig. 2From: A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteersFlow diagram of related adverse events (AEs) in S-1226 (4Â %, 8Â %, and 12Â % CO2) and placebo treatment groups based on their relationship to the drug (possibly or remotely). ECG electrocardiogram, WBC white blood cellBack to article page